Franklin Genomic Advancements ETF (HELX)

BATS: HELX · Real-Time Price · USD

42.59

+0.65 (1.54%)

Oct 15, 2026, 4:00 PM EDT - Market closed

Assets	$33.33M
Expense Ratio	0.50%
PE Ratio	30.93
Forward PE	25.35
Shares Out	800,000
Dividend	$0.14 (0.34%)
Ex-Dividend Date	Dec 30, 2025
Payout Frequency	n/a
Payout Ratio	10.45%

Volume	1,320
Open	41.72
Previous Close	41.94
Day's Range	41.72 - 42.85
52-Week Low	31.24
52-Week High	45.58
Beta	0.96
Holdings	72
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

Asset Class Equity

Category Health

Region Global

Stock Exchange Cboe BZX

Ticker Symbol HELX

ETF Provider Franklin Templeton

Top 10 Holdings

49.28% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	10.32%
Guardant Health, Inc.	GH	9.40%
Krystal Biotech, Inc.	KRYS	5.36%
Adaptive Biotechnologies Corporation	ADPT	4.53%
Ligand Pharmaceuticals Incorporated	LGND	4.47%
Twist Bioscience Corporation	TWST	4.27%
BridgeBio Pharma, Inc.	BBIO	2.90%
Medpace Holdings, Inc.	MEDP	2.77%
United Therapeutics Corporation	UTHR	2.63%
Vertex Pharmaceuticals Incorporated	VRTX	2.62%

View More Holdings

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 30, 2025	$0.14334	Jan 8, 2026
Dec 30, 2021	$0.00394	Jan 7, 2022
Dec 13, 2021	$0.11415	Dec 21, 2021
Dec 14, 2020	$0.05178	Dec 23, 2020

Full Dividend History

Performance

HELX had a total return of 31.56% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.09%.